# Optimising Group Sequential and Adaptive Designs:

## Where Frequentist meets Bayes

### Christopher Jennison

Department of Mathematical Sciences,

University of Bath, UK

http://people.bath.ac.uk/mascj

### Imperial College

London

*November 2018*

# Group Sequential and Adaptive Designs

Group sequential and adaptive clinical trial designs have been proposed for a number of important applications:

Early stopping for efficacy or futility,

Sample size modification,

Treatment selection and testing (seamless Phase 2/3 trials),

Population selection and testing (enrichment designs).

There are usually options to choose from within such a design.

How should one make such choices and assess the end result?

# Choosing an adaptive design

A key requirement for any Phase 3 trial is to protect the type I error rate.

This can be a complex problem when there are multiple null hypotheses under consideration — and multiple parameters, so the type I error rate must be controlled over a high-dimensional region.

Then, one wishes to be efficient, gaining high power with low sample size.

**Question**

How should one make decisions:

At interim analyses?

At the final analysis?

# Outline of talk

1. Monitoring clinical trials

   Group sequential stopping rules

   Sample size modification

2. Seamless Phase 2/3 designs

   Designs that protect family-wise error rate,

   Optimising decision rules and sample size allocation.

3. Enrichment designs

   Adaptive enrichment in response to interim data.

   Optimising the decision rule for when to enrich.

4. Conclusions

# 1. Early stopping and sample size re-estimation

A clinical trial is run to compare a new treatment with an existing treatment or placebo.

As the trial progresses, a Data and Safety Monitoring Board (DSMB) monitors patient recruitment, treatment administration, and the responses observed at interim points.

The DSMB can take actions in view of safety variables or secondary endpoints, for example, to drop a treatment arm with a high dose level if this appears unsafe.

Response on the primary endpoint may indicate that early termination of the study is desirable — for either a positive or negative conclusion.

# The need for special methods

Multiple looks at accumulating data can lead to over-interpretation of interim results.

Armitage et al. (*JRSS, A*, 1969) report the overall type I error rate when applying repeated significance tests at level $\alpha = 0.05$ to accumulating data:

| Number of tests | Error rate |
|:---:|:---:|
| 1 | 0.05 |
| 2 | 0.08 |
| 3 | 0.11 |
| 5 | 0.14 |
| 10 | 0.19 |

Clearly, a different approach is needed to avoid inflation of the type I error rate.

# Formulating the problem

Let $\theta$ denote the "effect size", a measure of the improvement in the new treatment over the standard.

We shall test the null hypothesis $H_0$: $\theta \leq 0$ against $\theta > 0$.

Then, rejecting $H_0$ allows us to conclude the new treatment is better than the standard.

We allow type I error probability $\alpha$ for rejecting $H_0$ when it is actually true.

We specify power $1 - \beta$ for the probability of (correctly) rejecting $H_0$ when $\theta = \delta$. Here, $\delta$ is, typically, the minimal clinically significant treatment difference.

The trial design, including the method of analysis and stopping rule, must be set up to attain these error rates.

# An early example: The BHAT trial

DeMets et al. (*Cont. Clin. Trials*, 1984) report on the Beta-Blocker Heart Attack Trial, that compared propanolol with placebo.

An "O'Brien and Fleming" stopping boundary was defined with overall type I error probability 0.025.



The trial stopped after the 6th of 7 planned analyses.

# Group sequential tests: Stopping for futility

Adding a lower boundary allows stopping when there is little chance of a positive conclusion.



Rosner & Tsiatis (*Statistics in Medicine*, 1989) carried out retrospective analyses of 72 cancer studies of the U.S. Eastern Co-operative Oncology Group.

Had group sequential stopping rules been applied, early stopping (mostly to accept $H_0$) would have occurred in ∼80% of cases.

# Requirements for clinical trial designs

We seek designs which:

*Achieve specified type I error rate and power,*

*Stop early, on average, under key parameter values,*

*Can be applied to a variety of response types.*

We shall present distribution theory which shows that a common set of methods can be applied to many data types.

To define efficient tests, we shall formulate and solve an optimal stopping problem.

# Sequential distribution theory

Our interest is in the parameter for the treatment effect, $\theta$.

Let $\widehat{\theta}_k$ denote the estimate of $\theta$ based on data at analysis $k$.

The information for $\theta$ at analysis $k$ is

$$\mathcal{I}_k = \{\mathsf{Var}(\widehat{\theta}_k)\}^{-1}, \quad k = 1, \ldots, K.$$

## Canonical joint distribution of $\widehat{\theta}_1, \ldots, \widehat{\theta}_K$

In many situations, $\widehat{\theta}_1, \ldots, \widehat{\theta}_K$ are approximately multivariate normal,

$$\widehat{\theta}_k \sim N(\theta, \{\mathcal{I}_k\}^{-1}), \quad k = 1, \ldots, K,$$

and

$$\mathsf{Cov}(\widehat{\theta}_{k_1}, \widehat{\theta}_{k_2}) = \mathsf{Var}(\widehat{\theta}_{k_2}) = \{\mathcal{I}_{k_2}\}^{-1} \quad \text{for } k_1 < k_2.$$

# Canonical joint distribution of score statistics

The preceding result about the joint distribution of $\widehat{\theta}_1, \ldots, \widehat{\theta}_K$ can be demonstrated directly for:

$\theta$ *a single normal mean,*

$\theta = \mu_A - \mu_B$, *comparing two normal means.*

The results also apply when $\theta$ is a parameter in:

*a general normal linear model,*

*a model fitted by maximum likelihood (large sample theory),*

*a Cox proportional hazards regression model for survival data.*

Thus, theory supports general comparisons, including:

*crossover trials, studies with longitudinal data,*

*analyses with covariate adjustment.*

# Canonical joint distribution of score statistics

The general theory implies that *score statistics*, $S_k = Z_k \sqrt{\mathcal{I}_k}$, are multivariate normal with

$$S_k \sim N(\theta \, \mathcal{I}_k, \, \mathcal{I}_k), \quad k = 1, \ldots, K.$$

The score statistics have the "independent increments" property

$$\text{Cov}(S_k - S_{k-1}, \, S_{k'} - S_{k'-1}) = 0 \quad \text{for } k \neq k'.$$

It can be helpful to know that the score statistics behave as Brownian motion with drift $\theta$ observed at times $\mathcal{I}_1, \ldots, \mathcal{I}_K$.

*References:*

Jennison & Turnbull, *JASA*, 1997,

Scharfstein et al, *JASA*, 1997.

# An optimal stopping problem

Consider a trial designed to test $H_0$: $\theta \leq 0$ vs $\theta > 0$, with:

Type I error rate $\alpha$,

Power $1 - \beta$ at $\theta = \delta$,

Up to $K$ analyses.

A fixed sample test needs information

$$\mathcal{I}_{fix} = \{\Phi^{-1}(\alpha) + \Phi^{-1}(\beta)\}^2/\delta^2.$$

We set the maximum information to be

$$\mathcal{I}_{max} = R\mathcal{I}_{fix},$$

where $R > 1$, with equal increments between analyses.

# Optimal group sequential tests

The error rates impose two constraints on the $2K - 1$ boundary points — leaving a high dimensional space of possible boundaries.



We shall look for a boundary that minimises

$$\{E_0(\mathcal{I}) + E_\delta(\mathcal{I})\}/2.$$

# Computations for group sequential tests



We need to be able to calculate the probabilities of basic events such as

$$a_1 < Z_1 < b_1, \ \ a_2 < Z_2 < b_2, \ \ Z_3 > b_3.$$

Combining such probabilities gives key properties, such as $Pr_\theta\{\text{Reject } H_0\}$ and $E_\theta(\mathcal{I})$.

## Numerical integration

We can write probabilities as nested integrals, e.g.,

$$Pr\{a_1 < Z_1 < b_1, \, a_2 < Z_2 < b_2, \, Z_3 > b_3\} =$$

$$\int_{a_1}^{b_1} \int_{a_2}^{b_2} \int_{b_3}^{\infty} f_1(z_1) \, f_2(z_2|z_1) \, f_3(z_3|z_2) \, dz_3 \, dz_2 \, dz_1.$$

Applying numerical integration, we replace each integral by a sum of the form

$$\int_a^b f(z) \, dz \; = \; \sum_{i=1}^{n} w(i) \, f(z(i)),$$

where $z(1), \ldots, z(n)$ is a grid of points from $a$ to $b$.

# Numerical integration

Thus, we have

$$Pr\{a_1 < Z_1 < b_1,\ a_2 < Z_2 < b_2,\ Z_3 > b_3\} \approx$$

$$\sum_{i_1=1}^{n_1} \sum_{i_2=1}^{n_2} \sum_{i_3=1}^{n_3} w_1(i_1)\, f_1(z_1(i_1))\, w_2(i_2) f_2(z_2(i_2)|z_1(i_1))$$

$$w_3(i_3)\, f_3(z_3(i_3)|z_2(i_2)).$$

Multiple integrations and summations will arise, e.g., for an outcome at analysis $k$,

$$\sum_{i_1=1}^{n_1} \ldots \sum_{i_k=1}^{n_k} w_1(i_1)\, f_1(z_1(i_1))\, w_2(i_2) f_2(z_2(i_2)|z_1(i_1))$$

$$\ldots\ w_k(i_k)\, f_k(z_k(i_k)|z_{k-1}(i_{k-1})).$$

# Numerical integration

In the multiple summation

$$\sum_{i_1=1}^{n_1} \sum_{i_2=1}^{n_2} \ldots \sum_{i_k=1}^{n_k} w_1(i_1)\, f_1(z_1(i_1))\, w_2(i_2) f_2(z_2(i_2)|z_1(i_1))$$

$$\ldots\ w_k(i_k)\, f_k(z_k(i_k)|z_{k-1}(i_{k-1})),$$

the structure of the $k$ nested summations is such that the computation required is of the order of $k-1$ double summations.

Using Simpson's rule with 100 to 200 grid points per integral can give accuracy to 5 or 6 decimal places.

For details of efficient sets of grid points, see Ch. 19 of *Group Sequential Methods with Applications to Clinical Trials* by Jennison and Turnbull (2000).

# Finding optimal group sequential tests

Recall, we want a group sequential test of $H_0: \theta \leq 0$ vs $\theta > 0$ with

$Pr_{\theta=0}\{\text{Reject } H_0\} = \alpha$,

$Pr_{\theta=\delta}\{\text{Accept } H_0\} = \beta$,

Analyses at $\mathcal{I}_k = (k/K)\,\mathcal{I}_{max}, \quad k = 1, \ldots, K$,

Minimum possible value of $\{E_0(\mathcal{I}) + E_\delta(\mathcal{I})\}/2$.

We deal with constraints on error rates by introducing Lagrangian multipliers to create the *unconstrained problem* of minimising

$$\{E_0(\mathcal{I}) + E_\delta(\mathcal{I})\}/2 + \lambda_1 Pr_{\theta=0}\{\text{Reject } H_0\} + \lambda_2\, Pr_{\theta=\delta}\{\text{Accept } H_0\}.$$

We shall find a pair of multipliers $(\lambda_1, \lambda_2)$ such that the solution has type I and II error rates $\alpha$ and $\beta$, then this design will solve the *constrained problem* too.

# Bayesian interpretation of the Lagrangian approach

Suppose we put a prior on $\theta$ with $Pr\{\theta = 0\} = Pr\{\theta = \delta\} = 0.5$ and specify costs of

$$1 \qquad \text{per unit of information observed,}$$

$$2\,\lambda_1 \quad \text{for rejecting } H_0 \text{ when } \theta = 0,$$

$$2\,\lambda_2 \quad \text{for accepting } H_0 \text{ when } \theta = \delta.$$

Then, the total Bayes risk is

$$\{E_0(\mathcal{I}) + E_\delta(\mathcal{I})\}/2 + \lambda_1\, Pr_{\theta=0}\{\text{Reject } H_0\} + \lambda_2\, Pr_{\theta=\delta}\{\text{Accept } H_0\},$$

just as in the Lagrangian problem.

An advantage of the Bayes interpretation is that it can give insight into solving the problem by using "Dynamic Programming" or "Backwards Induction".

# Solution by Dynamic Programming

Denote the posterior distribution of $\theta$ given $Z_k = z_k$ at analysis $k$ by

$$p^{(k)}(\theta|z_k), \quad \theta = 0, \, \delta.$$

## At the final analysis, $K$

There is no further sampling cost, so compare decisions

$$\text{Reject } H_0: \qquad E(\text{Cost}) = 2\,\lambda_1\,p^{(K)}(0|z_K),$$

$$\text{Accept } H_0: \qquad E(\text{Cost}) = 2\,\lambda_2\,p^{(K)}(\delta|z_K).$$

The boundary point $a_K$ is the value of $z_K$ where these expected losses are equal.

The optimum decision rule is to reject $H_0$ for $Z_K > a_K$.

# Dynamic Programming

**At analysis $K-1$**



If the trial stops at this analysis, there is no further cost of sampling and the expected additional cost is

$$\text{Reject } H_0: \qquad 2\,\lambda_1\,p^{(K-1)}(0|z_{K-1}),$$

$$\text{Accept } H_0: \qquad 2\,\lambda_2\,p^{(K-1)}(\delta|z_{K-1}).$$

If the trial continues to analysis $K$, the expected additional cost is

$$1 \times (\mathcal{I}_K - \mathcal{I}_{K-1})$$

$$+ \, 2 \, \lambda_1 \, p^{(K-1)}(0|z_{K-1}) \, Pr_{\theta=0}\{Z_K > a_K | Z_{K-1} = z_{K-1}\}$$

$$+ \, 2 \, \lambda_2 \, p^{(K-1)}(\delta|z_{K-1}) \, Pr_{\theta=\delta}\{Z_K < a_K | Z_{K-1} = z_{K-1}\}.$$

We can now define the optimal boundary points:

Set $b_{K-1}$ to be the value of $z_{K-1}$ where

$E(\text{Cost of continuing}) \; = \; E(\text{Cost of stopping to reject } H_0)$.

Set $a_{K-1}$ to be the value of $z_{K-1}$ where

$E(\text{Cost of continuing}) \; = \; E(\text{Cost of stopping to accept } H_0)$.

# At analysis $K-1$



Before leaving analysis $K-1$, we set up a grid of points for use in numerical integration over the range $a_{K-1}$ to $b_{K-1}$.

For each point, we sum over the posterior distribution of $\theta$ to calculate

$$\beta^{(K-1)}(z_{K-1}) = E(\text{Additional cost when continuing} \,|\, Z_{K-1} = z_{K-1}).$$

We are now ready to move back to analysis $K-2$.

# Analyses 1 to $K-2$

We work back through analyses $k = K-2, K-3, \ldots, 1$.



At each analysis, we find the optimal stopping boundary using knowledge of the optimal stopping rule at future analyses.

Then, for a grid of values of $z_k$, compute

$$\beta^{(k)}(z_k) = E(\text{Additional cost when continuing} \,|\, Z_k = z_k)$$

to use in evaluating the option of continuing at analysis $k-1$.

# Solving the original problem

For any given $(\lambda_1, \lambda_2)$ we can find the Bayes optimal design and compute its type I and II error rates.

We now search for a pair $(\lambda_1, \lambda_2)$ for which type I and type II error rates of the optimal design equal $\alpha$ and $\beta$, respectively.

The resulting design will be the optimal group sequential test, with the specified frequentist error rates, for our original problem.

**Notes**

1. The method of solving the overall problem demonstrates explicitly that good frequentist procedures should be similar to Bayes procedures.

2. The prior and costs in the final Bayes problem are a means to an end, rather than "true" costs of type I and type II errors, or costs of treating patients in the trial.

# Properties of optimal designs

Tests with $\alpha = 0.025$, $1 - \beta = 0.9$, $K$ analyses, $\mathcal{I}_{max} = R\mathcal{I}_{fix}$,
equal group sizes, minimising $\{E_0(\mathcal{I}) + E_\delta(\mathcal{I})\}/2$.

**Minimum values of $\{E_0(\mathcal{I}) + E_\delta(\mathcal{I})\}/2$, as a percentage of $\mathcal{I}_{fix}$**

| $K$ | $R$ 1.01 | 1.05 | 1.1 | 1.2 | 1.3 | Minimum over $R$ |
|---|---|---|---|---|---|---|
| 2 | 80.8 | 74.7 | 73.2 | 73.7 | 75.8 | 73.0 at $R$=1.13 |
| 5 | 72.2 | 65.2 | 62.2 | 59.8 | 59.0 | 58.8 at $R$=1.38 |
| 10 | 69.2 | 62.2 | 59.0 | 56.3 | 55.1 | 54.2 at $R$=1.6 |
| 20 | 67.8 | 60.6 | 57.5 | 54.6 | 53.3 | 51.7 at $R$=1.8 |

Observe: $E(\mathcal{I}) \searrow$ as $K \nearrow$ but with diminishing returns,

$E(\mathcal{I}) \searrow$ as $R \nearrow$ up to a point.

# Generalisations

Solutions can be obtained for a variety of related problems:

- Other optimality criteria such as a weighted sum

$$\sum_i w_i E_{\theta_i}(\mathcal{I})$$

  or an integral

$$\int f(\theta)\, E_\theta(\mathcal{I})\, d\theta$$

- Optimising a set of fixed group sizes in a group sequential test

- Data dependent group sizes in a group sequential test

- Group sequential tests for a delayed response

- Testing for either superiority or non-inferiority

# Adaptive sample size modification in clinical trials: start small then ask for more?

**Christopher Jennison[a*‡] and Bruce W. Turnbull[b]**

We consider sample size re-estimation in a clinical trial, in particular when there is a significant delay before the measurement of patient response. Mehta and Pocock have proposed methods in which sample size is increased when interim results fall in a 'promising zone' where it is deemed worthwhile to increase conditional power by adding more subjects. Our analysis reveals potential pitfalls in applying this approach. Mehta and Pocock use results of Chen, DeMets and Lan to identify when increasing sample size, but applying a conventional level $\alpha$ significance test at the end of the trial does not inflate the type I error rate: we have found the greatest gains in power per additional observation are liable to lie outside the region defined by this method. Mehta and Pocock increase sample size to achieve a particular conditional power, calculated under the current estimate of treatment effect: this leads to high increases in sample size for a small range of interim outcomes, whereas we have found it more efficient to make moderate increases in sample size over a wider range of cases. If the aforementioned pitfalls are avoided, we believe the broad framework proposed by Mehta and Pocock is valuable for clinical trial design. Working in this framework, we propose sample size rules that apply explicitly the principle of adding observations when they are most beneficial. The resulting trial designs are closely related to efficient group sequential tests for a delayed response proposed by Hampson and Jennison. Copyright © 2015 John Wiley & Sons, Ltd.

**Keywords:**    group sequential test; sample size re-estimation; adaptive design; clinical trial; optimal design; promising zone

# Sample size re-estimation

In a group sequential trial, the final sample size depends on the observed data.

"Sample size re-estimation" gives another route to a similar end.

**Example 1** of Mehta & Pocock (*Statistics in Medicine*, 2011) concerns a Phase 3 trial of a new treatment for schizophrenia, comparing the new drug to an active control.

The efficacy endpoint is improvement in the Negative Symptoms Assessment score from baseline to week $26$.

Responses are

$$Y_{Bi} \sim N(\mu_B, 7.5^2), \;\; i = 1, 2, \ldots, \;\; \text{on the new treatment,}$$

$$Y_{Ai} \sim N(\mu_A, 7.5^2), \;\; i = 1, 2, \ldots, \;\; \text{on the control arm,}$$

and the treatment effect is $\theta = \mu_B - \mu_A$.

# Sample size re-estimation

The initial plan is for $n_2 = 442$ patients, 221 on each treatment.

In testing $H_0$: $\theta \leq 0$ vs $\theta > 0$ at the final analysis, we reject $H_0$ if

$$Z_2 = \frac{\hat{\theta}(n_2)}{\sqrt{\{4\sigma^2/n_2\}}} > 1.96.$$

This design and analysis gives type I error rate $0.025$ and power $0.8$ at $\theta = 2$.

Higher power, e.g., power $0.8$ at $\theta = 1.6$, would be desirable.

The sponsors are willing to increase sample size if interim results are "promising".

An interim analysis is planned after observing $n_1 = 208$ responses.

**Delayed response:** At this time a further $208$ subjects will have been admitted to the trial, but treated for less than $26$ weeks.

# Sample size re-estimation

We consider the following variation on Mehta & Pocock's "Promising zone" design.

At the interim analysis with $n_1 = 208$ observed responses, the estimated treatment effect is

$$\widehat{\theta}_1 = \overline{Y}_B(1 : n_1/2) - \overline{Y}_A(1 : n_1/2)$$

and

$$Z_1 = \frac{\widehat{\theta}_1}{\sqrt{\{4\sigma^2/n_1\}}}.$$

In the remainder of the trial a further $n_2^* - n_1$ observations provide

$$\widehat{\theta}_2 = \overline{Y}_B(n_1/2 + 1 : n_2^*/2) - \overline{Y}_A(n_1/2 + 1 : n_2^*/2)$$

and

$$Z_2 = \frac{\widehat{\theta}_2}{\sqrt{\{4\sigma^2/(n_2^* - n_1)\}}}.$$

At the end of the trial, we test $H_0$: $\theta \leq 0$ with a combination test, rejecting $H_0$ if

$$\frac{1}{\sqrt{2}}\, Z_1 + \frac{1}{\sqrt{2}}\, Z_2 \;>\; 1.96.$$

In this framework, we are free to vary $n_2^*$ and the final test will still have one-sided type I error rate $\alpha = 0.025$.

Given the 208 subjects "in the pipeline", we must take $n_2^* \geq 416$, but we can increase $n_2^*$ beyond the planned value of $442$ in order to increase power.

**Questions:**

What is an efficient way to choose $n_2^*$ based on the observed $\widehat{\theta}_1$?

How should we formulate the problem to pose this question in a precise way?

## Problem formulation (Jennison & Turnbull, *SiM*, 2015)

We specify $\gamma$, a "rate of exchange" between sample size and power. Focusing on properties under $\theta = \tilde{\theta} = 1.6$, we aim to maximise

$$P_{\theta=\tilde{\theta}}(\text{Reject } H_0) - \gamma E_{\tilde{\theta}}(N). \qquad (1)$$

Denote the conditional power under $\theta = \tilde{\theta}$ of the combination test, given $Z_1 = z_1$ and a total sample size of $n_2^*$, by

$$CP_{\tilde{\theta}}(z_1, n_2^*) = P_{\tilde{\theta}}\{\frac{1}{\sqrt{2}} Z_1 + \frac{1}{\sqrt{2}} Z_2 > 1.96 \mid Z_1 = z_1, n_2^*\}.$$

We aim to find the sample size function $n_2^*(z_1)$ that maximises (1). This objective can be written as

$$\int \{CP_{\tilde{\theta}}(z_1, n_2^*(z_1)) - \gamma n_2^*(z_1)\} f_{\tilde{\theta}}(z_1) \, dz_1,$$

where $f_{\tilde{\theta}}(z_1)$ denotes the density of $Z_1$ under $\theta = \tilde{\theta}$.

# Problem formulation

In order to maximise

$$\int \left\{ CP_{\tilde{\theta}}(z_1, n_2^*(z_1)) - \gamma n_2^*(z_1) \right\} f_{\tilde{\theta}}(z_1) \, dz_1,$$

for each $z_1$, we need to choose $n_2^*(z_1)$ to maximise

$$CP_{\tilde{\theta}}(z_1, n_2^*(z_1)) - \gamma n_2^*(z_1).$$

Here, the optimisation can be done by numerical calculation under a range of possible values for $n_2^*$.

Combining these results for different values of $z_1$ gives the optimised sample size rule $n_2^*(z_1)$.

# Maximising $CP_{\widetilde{\theta}}(z_1, n_2^*) - \gamma(n_2^* - 442)$

**Plots for $\tilde{\theta} = 1.6$, $\gamma = 0.245/(4\,\sigma^2)$ and $\widehat{\theta}_1 = 0.75$**



The function $CP_{\widetilde{\theta}}(z_1, n_2^*) - \gamma(n_2^* - 442)$ attains its maximum at $n_2^* = 589$.

# Maximising $CP_{\widetilde{\theta}}(z_1, n_2^*) - \gamma(n_2^* - 442)$

**Plots for $\widetilde{\theta} = 1.6$, $\gamma = 0.245/(4\,\sigma^2)$ and $\widehat{\theta}_1 = 1.25$**



For $\widehat{\theta}_1 = 1.25$, conditional power rises less steeply as $n_2^*$ increases.

Now, the function $CP_{\widetilde{\theta}}(z_1, n_2^*) - \gamma(n_2^* - 442)$ has its maximum at $n_2^* = 570$.

**Optimal sample size rule for combination test design**
**with $n_2^*$ in $(416, 884)$, $\tilde{\theta} = 1.6$, $\gamma = 0.245/(4\,\sigma^2)$**



With $\gamma = 0.245/(4\,\sigma^2)$, overall power is $0.658$ at $\theta = 1.6$ (the same as for the MP Promising Zone design).

By construction, the procedure has minimum $E_{\theta=1.6}(N)$ among all normal combination test designs with $n_1 = 208$ and $n_2^* \geq 416$ that achieve the same power.

**Combination test design with optimal sample size rule: $n_2^* \geq 416,\ \tilde{\theta} = 1.6,\ \gamma = 0.245/(4\,\sigma^2)$**

Power curve

$E_\theta(N)$ curves



The optimised design has the same power curve as a fixed sample size design with 490 patients — and lower $E_\theta(N)$ at all $\theta$ values.

# Other options

1. We could reduce the value of $\gamma$, leading to an increase in sample size and higher power.

2. We could optimise other criteria, replacing $E_{\tilde{\theta}}(N)$ in $P_{\theta=\tilde{\theta}}(\text{Reject } H_0) - \gamma E_{\tilde{\theta}}(N)$ by a weighted sum or integral,

$$\sum_i w_i\, E_{\theta_i}(N) \quad \text{or} \quad \int w(\theta)\, E_\theta(N)\, d\theta.$$

In the integral case, treating the power function in a similar way, we seek to maximise

$$\int w(\theta)\, P_\theta(\text{Reject } H_0)\, d\theta - \gamma \int w(\theta)\, E_\theta(N)\, d\theta.$$

If $w(\theta)$ is a prior distribution, representing investigators' beliefs about likely values of $\theta$, we have a Bayes decision problem.

# Other options

Suppose we wish to maximise

$$\int w(\theta) \, P_\theta \left(\text{Reject } H_0\right) d\theta \; - \; \gamma \int w(\theta) \, E_\theta(N) \, d\theta.$$

For each $z_1$, we must choose $n_2^*(z_1)$ to maximise

$$CP(z_1, n_2^*(z_1)) - \gamma n_2^*(z_1),$$

where $CP(z_1, n_2^*(z_1))$ is the conditional power *integrated over the posterior distribution of* $\theta$ given the stage 1 data summary $z_1$.

By working within the class of inverse normal combination tests, we automatically protect the type I error rate at level $\alpha$.

We can choose $\gamma$ to meet a specific power condition. Since the set of possible power curves is essentially a one-parameter family, precisely how power appears in the objective function is not crucial.

# Other options

3. Additional constraints can be included in the design process:

   - One could set an upper limit on values for $n_2^*$.

   - Investors may only wish to consider an increase in sample size when results are deemed to be sufficiently "promising".

4. The sample size rule can be simplified by allowing just two possible values for $n_2^*$.

When optimised, this simpler design can achieve almost the same $E_\theta(N)$ function as designs with a more general form of $n_2^*(z_1)$.

Such a design is an example of a "Delayed Response Group Sequential Design"; see Hampson & Jennison, (*JRSS, B*, 2013).

# 2. Optimising a Phase 2/3 seamless design

During Phase 2 and Phase 3 of the drug development process,

The final decision is made on the treatment specification, including the dose level,

The selected treatment is tested against control.

A seamless Phase 2/3 trial design combines these two phases:

In stage 1

Compare $K$ "treatments" against control

Select the best treatment and, if it has performed sufficiently well, proceed to stage 2.

In stage 2

Compare the selected treatment against the control.

After both stages are completed, we test the null hypothesis that the selected treatment is no better than the control.

Since this treatment was selected based on data that will also be used in the final analysis, care must be taken to avoid inflating the overall type I error rate.

**Design issues**

We would like to optimise:

1. The way in which data on all treatments are combined in the final hypothesis test,

2. The way in which the total sample size is divided between the two stages.

# Optimizing the data combination rule for seamless phase II/III clinical trials

## Lisa V. Hampson[a*†] and Christopher Jennison[b]

We consider seamless phase II/III clinical trials that compare $K$ treatments with a common control in phase II then test the most promising treatment against control in phase III. The final hypothesis test for the selected treatment can use data from both phases, subject to controlling the familywise type I error rate. We show that the choice of method for conducting the final hypothesis test has a substantial impact on the power to demonstrate that an effective treatment is superior to control. To understand these differences in power, we derive decision rules maximizing power for particular configurations of treatment effects. A rule with such an optimal frequentist property is found as the solution to a multivariate Bayes decision problem. The optimal rules that we derive depend on the assumed configuration of treatment means. However, we are able to identify two decision rules with robust efficiency: a rule using a weighted average of the phase II and phase III data on the selected treatment and control, and a closed testing procedure using an inverse normal combination rule and a Dunnett test for intersection hypotheses. For the first of these rules, we find the optimal division of a given total sample size between phases II and III. We also assess the value of using phase II data in the final analysis and find that for many plausible scenarios, between 50% and 70% of the phase II numbers on the selected treatment and control would need to be added to the phase III sample size in order to achieve the same increase in power. © 2014 The Authors. *Statistics in Medicine* published by John Wiley & Sons Ltd.

**Keywords:** Bayes decision problem; combination test; closed testing procedure; multiple hypothesis testing; seamless phase II/III trial; treatment selection

# Optimising a Phase 2/3 seamless design

Denote the $K$ treatment effects vs control by $\theta_1, \ldots, \theta_K$.

**Stage 1**

Randomise $m_1$ subjects to each of the $K$ treatments and the control and observe their responses.

Denote the estimated treatment effects by $\widehat{\theta}_{1,i}, \; i = 1, \ldots, K$.

Treatment $i^*$ with the highest $\widehat{\theta}_{1,i}$ is selected for stage 2.

**Stage 2**

Treatment $i^*$ is compared against control, with $m_2$ observations on each. The estimated treatment effect is $\widehat{\theta}_{2,i^*}$.

**Conclusion**

A final decision is made, based on $\widehat{\theta}_{1,1}, \ldots, \widehat{\theta}_{1,K}$ and $\widehat{\theta}_{2,i^*}$.

# Optimising a Phase 2/3 seamless design

There are $K$ null hypotheses, $H_i$: $\theta_i \leq 0$, $i = 1, \ldots, K$.

If dose $i^*$ is selected for Phase 3, we focus on testing $H_{i^*}$: $\theta_{i^*} \leq 0$.

## Family-wise error

We want strong control of the **family-wise error** rate. Then, for all vectors $\theta = (\theta_1, \ldots, \theta_K)$,

$$Pr_\theta\{\text{Reject } \textit{any} \text{ true } H_i\} \leq \alpha.$$

## Power

When some $\theta_i$ are greater than zero, we can define power as

$Pr\{\text{Select treatment } j \text{ with maximum } \theta_i \text{ and reject } H_j\colon \theta_j \leq 0\}.$

More generally, we can define a gain function or utility that is positive when $H_{i^*}$ is rejected, whichever treatment is selected, but the gain increases with $\theta_{i^*}$.

# Optimising a Phase 2/3 seamless design

The family-wise error rate can be controlled by using a Closed Testing Procedure.

This requires level $\alpha$ tests of each null hypothesis $H_i$, and of all intersections of sets of these hypotheses.

Each of these tests can be constructed as a combination test across the two stages of the trial.

Then, general theory implies that the family-wise type 1 error rate is controlled at level $\alpha$.

There are still choices to be made:

How should we test the intersection hypotheses in stage 1?

What type of combination test is best?

The best choice may depend on the $K$-dimensional parameter $\theta$.

# Optimising a Phase 2/3 seamless design

Hampson & Jennison (*Statistics in Medicine*, 2013) found optimal final decision rules that maximise power when $\theta = \delta v$, for various choices of vector $v$.

Interestingly, two procedures were close to 100% efficient across a wide range of scenarios.

1. In the framework we have described, use a Dunnett test for each intersection hypothesis in stage 1 and combine $Z$ values across stages with a weighted normal combination test.

2. Use the procedure proposed by Thall, Simon and Ellenberg (*Biometrika*, 1988).

We were surprised that procedures with such robust efficiency exist.

However, this deals conveniently with the issue that the best design may depend on a high-dimensional, unknown vector $\theta$.

# Optimising a Phase 2/3 seamless design

Hampson & Jennison also considered how best to divide a total sample size between stage 1 ($m_1$ observations on $K$ treatments and control) and stage 2 ($m_2$ on selected treatment and control).

The choice that maximises power depends on the vector of treatment effects, $\theta$, with the largest treatment effect playing a leading role.

If the highest treatment effect is large, one can afford a high $m_1$, increasing the probability of selecting this treatment.

If the highest treatment effect is smaller, a high $m_2$ is needed to give power in stage 2 when the best treatment is selected.

**Advice:**

Express your expectations as a distribution for $\theta$ and choose a design with good average properties across this distribution.

**Figure 4.** (a) Stage 1 group sizes maximizing the power of the TSE procedure when the total sample size is fixed at 448 and $\theta$ is a random permutation (1) of $(0, 0, 0, 0, 1)\delta$, (2) of $(0.5, 0.5, 0.5, 0.5, 1)\delta$, (3) of $(0.75, 0.75, 0.75, 0.75, 1)\delta$, (4) of $(0.3, 0.475, 0.65, 0.825, 1)\delta$ and (5) of $(0.75, 0.8125, 0.875, 0.9375, 1)\delta$. (b) Power achieved by the optimized TSE procedures. Decision rules are listed in order of decreasing power. Designs are specified with $K = 5$, $\ell = 0$, $\sigma = 5.0$ and $\alpha = 0.025$. Results are based on 1 million simulations for each scenario.

# Benefits of Phase 2/3 seamless designs

Regulators require a seamless Phase 2/3 trial to be conducted as a single trial, with a firewall between the data monitoring committee and the investigators.

Efficiency gains from using "Phase 2" data in the final hypothesis test must balance extra planning and organisational requirements.

With $m_1$ observations on each treatment and control in stage 1 and $m_2$ on the selected treatment and control in stage 2, what are the benefits of using the stage 1 data in the final analysis?

Hampson & Jennison show that:

> If only Phase 3 data are used in the final analysis, then in many plausible scenarios, $m_2$ needs to be increased by between $0.5m_1$ and $0.7m_1$, in order to achieve the same power as the seamless design.

# Comments on this example

**Controlling the frequentist type I error rate**

Use of a closed testing procedure and combination tests guarantees control of type I error.

**Optimising within this class of designs**

We can, essentially, optimise the choice of closed testing procedure and combination test for all treatment effect vectors, $\theta$.

However, the best choice of sample sizes in stage 1 and stage 2 does depend on the vector $\theta$.

The Bayes solution is to specify a prior distribution for the unknown $\theta$ and optimise performance integrated over this distribution.

**An outer layer**

If the optimised value of $m_1$ leads to unacceptably low average power, consider a higher total sample size for the two stages.

**Switching to a sub-population in response to interim data**

Consider a treatment developed to disrupt a disease's biological pathway. Patients with high levels of a biomarker for this pathway should gain particular benefit.

In a clinical trial with **enrichment** we

Start by comparing the new treatment against control in the full population.

Examine responses at an interim stage and decide whether to:

Stop for futility,

Continue recruiting from the full population,

Continue, but recruit only from the subgroup — and increase their numbers.

Results may support a licence for the full population or just the sub-population.

# Creating an efficient enrichment design

Sub-population $\theta_1$ $\theta_2$ Rest of the population

(proportion $\lambda_1$)        (proportion $\lambda_2$)

The treatment effect (difference in mean response between new treatment and control) is $\theta_1$ in the sub-population and $\theta_2$ in the complement of this sub-population.

The treatment effect over the full population is $\theta_3 = \lambda_1\theta_1 + \lambda_2\theta_2$.

We may wish to test either or both of:

The null hypothesis for the full population, $H_3$: $\theta_3 \leq 0$ vs $\theta_3 > 0$,

The null hypothesis for the sub-population, $H_1$: $\theta_1 \leq 0$ vs $\theta_1 > 0$.

# Creating an efficient enrichment design

As in the adaptive seamless Phase 2/3 design, we want to control strongly the **family-wise error** rate.

Then, for all values of $\theta_1$ and $\theta_3$,

$$Pr\{\text{Reject } any \text{ true } H_i\} \leq \alpha.$$

This can be achieved by a "closed testing procedure", involving level $\alpha$ tests of $H_1$, $H_3$ and the intersection hypothesis $H_1 \cap H_3$.

Each of these tests can be constructed as a combination test across the two stages of the trial.

Then, general theory implies that the family-wise type 1 error rate is controlled at level $\alpha$.

This leaves freedom to define the rule for deciding whether or not to enrich at the interim analysis.

# Creating an efficient enrichment design

At the interim analysis, there are three options.



Optimising this decision rule requires specification of:

Benefits from rejecting $H_1$ or $H_3$ for parameter values $\theta_1$ and $\theta_3$,

The costs saved when the trial stops for futility,

A prior distribution for $(\theta_1, \theta_3)$.

# Creating an efficient enrichment design

At Bath, I have worked with Thomas Burnett on the derivation of optimal adaptive designs for enrichment trials.

The computation can be demanding, but Thomas has developed code to find optimal rules.

The appropriate adaptive decision rule depends strongly on the prior for $(\theta_1, \theta_3)$.

Once such a prior is specified, it is natural to compare simpler trial designs, that do not involve adaptation:

Recruit from the full population throughout the trial,

Recruit only from the sub-population throughout the trial.

We have found that, for some examples of gain function and prior, the best adaptive design is superior to both simple, non-adaptive designs — but this is not always the case.

However, even when a fixed sample design may be Bayes optimal — particularly when this is the design that restricts recruitment to the sub-population throughout the trial — we expect investigators may prefer an adaptive approach.

Not everyone has the same prior!

# Comments on this example

**Controlling the frequentist type I error rate**

Use of a closed testing procedure and combination tests guarantees control of family-wise type I error.

**Optimising within this class of designs**

Given gain and cost functions, and a prior distribution for $(\theta_1, \theta_3)$, one can compute Bayes-optimal adaptive enrichment designs.

**An outer layer**

Other design features that merit investigation include:

Details of the closed testing procedure and combination tests.

The timing of the interim analysis.

Preferential sampling of one population when the proportions $\lambda_1$ and $\lambda_2$ are away from $0.5$.

# 4. Overall conclusions

**Controlling the frequentist type I error rate**

We can apply closed testing procedures and combination tests to protect family-wise error in complex, high-dimensional settings.

We can then work on optimising other aspects of a given design.

**Optimising within a class of designs**

Before trying to optimise, we need to understand which properties of a design are important to the investigators.

Typically, this is done through the elicitation of their gain function, cost function, and prior distribution for unknown parameters.

Then, we can optimise by analysis, calculation or simulation.

**An outer layer**

Once we can optimise the central component of a design, we may re-visit higher level aspects and question initial assumptions.